Pharmaceutical giant Pfizer has now started to dose patients in its oral COVID-19 drug trial. The company said on Wednesday that it had started dosing in a mid-to-late-stage trial of its oral antiviral therapy for COVID-19 in non-hospitalized, symptomatic adult patients. In the mid-to-late-stage trial that has 1,140 participants, Pfizer would study the therapy, PF-07321332, … Continue reading “Pfizer Begins to Dose Patients in its Oral Covid-19 Drug Trial”
Tag: remdesivir
Biotech & Pharma
Sales for Covid-19 Drug Remdesivir Fall Short Prompting Gilead to Cut 2020 Sales Outlook
This week Gilead Sciences slashed its 2020 revenue forecast, citing lower than expected demand for…
October 30, 2020
Biotech & Pharma
FDA is in Discussions with Gilead to Make Remdesivir Available As Quickly as Possible
At the rate of how many are being infected with coronavirus and how many are…
April 29, 2020